Evaluation of Topical Chamomile Versus Topical Triamcinolone Acetonide in Management of Oral Lichen Planus

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03793634

Enrollment

Registered

2019-01-04

Start date

2019-01-15

Completion date

2020-03-01

Last updated

2019-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Lichen Planus

Brief summary

Using of herbal medications as topical chamomile which has antioxidant, anti-inflammatory and anticarcinogenesis effect with little side effects is the aim for the future treatment of OLP.

Detailed description

Oral lichen planus (OLP) is a chronic inflammatory T cell mediated autoimmune disease that affects skin and any mucous membrane particularly oral mucosa.The patient complains of burning sensation, pain; interference with eating, swallowing and speech leading to worsening of quality of life.Oxidative stress plays a role in pathomechanism of OLP disease. Enzymatic and non- enzymatic anti-oxidants act as a physiological guard against reactive oxygen species (ROS) and cytokine-mediated toxicity.Herbal treatment is the aim of the future therapy.Chamomile has anti-oxidant , anti-inflammatory effect and accelerate healing.

Interventions

DRUGtopical chamomile

herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Masking description

The supervisor(AA) will be blind. The principle investigator(EN) will supply the patient with the treatment. The supervisor (AA) will assess the clinical parameters before treatment , between visits and at the end of the treatment. Statistician will be blind. Double - blind study.

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Symptomatic OLP. * Patients with no history of taking corticosteroids for the last 6 months. * Patients who agree to take medication. * Medically free

Exclusion criteria

* Patients with oral lesions other than OLP. * Lichenoid reaction . * Pregnant females and lactation. * Smokers

Design outcomes

Primary

Measure	Time frame	Description
Pain using Numerical rating scale	1 month	Pain measure using Numerical rating scale

Secondary

Measure	Time frame	Description
clinical sign score	1 month	Reduction in clinical sign score using Thongprasom et al

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026